<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2096">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133882</url>
  </required_header>
  <id_info>
    <org_study_id>PCD-DHEC73543-16-002</org_study_id>
    <nct_id>NCT05133882</nct_id>
  </id_info>
  <brief_title>A Phase Ⅰb/Ⅱ Clinical Study of Crifortinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML</brief_title>
  <official_title>A Phase Ib/II, Multi-center, Open Clinical Trial of Crifortinib Besylate Combined With Chemotherapy in Newly-treated Adult Subjects With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center open clinical study aimed at evaluating the efficacy and safety of&#xD;
      Crifortinib Besylate combined with chemotherapy in newly-treated adult subjects with AML&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main purpose:To evaluate the tolerability and safety of Crifortinib Besylate combined with DA&#xD;
      (Cytarabine + Daunorubicin) or AZA (Azacitidine) in newly-treated adult AML subjects; explore&#xD;
      reasonable therapeutic doses through climbing tests in different dose groups.&#xD;
&#xD;
      To evaluate the efficacy of Crifortinib Besylate combined with DA or AZA in newly treated&#xD;
      adult AML subjects.&#xD;
&#xD;
      Secondary purpose:To observe the pharmacokinetic (PK) characteristics of Crifortinib combined&#xD;
      with DA or AZA in newly-treated adult AML subjects and the drug interaction between&#xD;
      Crifortinib and AZA at the same time.Observe the correlation of different subtypes and&#xD;
      prognostic risk with the efficacy of Crifortinib and the changes of genes before and after&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 12, 2022</start_date>
  <completion_date type="Anticipated">October 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Arm 1:30 mg Arm 2:40 mg Arm 3:60 mg</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose(MTD)</measure>
    <time_frame>day 1-28</time_frame>
    <description>Safety and Tolerability assessed through adverse events to determine maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite CR rate</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>CR + CRi +CRMRD-</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The time from receive CR / CRi/CRMRD-/PR to relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 12 months</time_frame>
    <description>CR + CRi +CRMRD- + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>up to 12 months</time_frame>
    <description>From the first time taking experimental drug to treatment failure or progression or relapse or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 12 months</time_frame>
    <description>From the first time taking experimental drug to death</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">133</enrollment>
  <condition>Acute Myeloid Leukemia, Adult</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Queue 1:Clifutinib Besylate:30mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:30mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Queue 1:Clifutinib Besylate:40mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:40mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Queue 1:Clifutinib Besylate:60mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:60mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clifutinib Besylate</intervention_name>
    <description>The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>HEC73543</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Cohort 1: 18 years old ≤ age ≤65 years old;Cohort 2: The dose escalation trial only&#xD;
             included AML subjects aged ≥60 years; the extended trial included subjects who were&#xD;
             ≥60 years old or between 18 and 59 years old (including 18 and 59 years old) and could&#xD;
             not tolerate strong chemotherapy.&#xD;
&#xD;
             2.It can be primary AML or AML secondary to MDS, and has not been treated; the&#xD;
             extension phase requires the subject to be positive for the FLT3-ITD mutation.&#xD;
&#xD;
             3.The ECOG score according to the requirements of different groups is as follows:&#xD;
             Cohort 1: 0~1 points; Cohort 2: Age ≥60 years old: 0~2 points; Age 18~59 years old&#xD;
             (including 18 and 59 years old): 0~3 points.&#xD;
&#xD;
             4.Expected survival time ≥ 12 weeks. 5. Subjects must have adequate organ function.&#xD;
             6.subjects voluntarily participated in the study, and signed a written informed&#xD;
             consent form by themselves or their guardians.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Diagnosed as APL and manifested as t(15;17)(q22;q12) chromosomal translocation, or&#xD;
             BCR-ABL positive leukemia；Diagnosed as secondary to AML due to previous chemotherapy&#xD;
             or radiotherapy of other tumors; previously received FLT3 inhibitor.&#xD;
&#xD;
             2.AML secondary to myeloproliferative tumor (MPN) or acute lymphoblastic leukemia&#xD;
             (ALL).&#xD;
&#xD;
             3.Subjects who have infiltrated the central nervous system in the past or present.&#xD;
&#xD;
             4.Concomitant with other malignant tumors within 5 years before the first medication.&#xD;
&#xD;
             5.Thrombosis or embolism occurred within 12 months before the first medication.&#xD;
             6.Pulmonary function tests indicate that subjects have DLCO ≤50% or FEV1 ≤60%, or have&#xD;
             difficulty breathing during rest or require continuous oxygen inhalation.&#xD;
&#xD;
             7.Subjects with uncontrollable, active infections。 8.Clinically obvious&#xD;
             gastrointestinal abnormalities, which may affect the intake, transport or absorption&#xD;
             of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction,&#xD;
             etc.), or subjects undergoing total gastrectomy。 9.Subjects with a history of&#xD;
             psychotropic drug abuse and unable to quit or those with mental disorders。&#xD;
             10.Researchers believe that those who have other severe acute or chronic diseases who&#xD;
             are not suitable for participating in clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Jin, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Jin, Doctor</last_name>
    <phone>0571-87236685</phone>
    <email>jiej0503@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital,College of Medicine,Zhejiang University</name>
      <address>
        <city>Hanzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

